62 research outputs found
Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma
<p>Abstract</p> <p>Background</p> <p>Protracted low-dose concurrent chemotherapy combined with radiation has been proposed for enhanced treatment results for esophageal cancer. We evaluated the efficacy and the toxicity of a novel regimen of daily low-dose nedaplatin (cis-diammine-glycolatoplatinum) and continuous infusion of 5-fluorouracil (5-FU) with radiation in patients with esophageal squamous cell carcinoma.</p> <p>Methods</p> <p>Between January 2003 and June 2008, 33 patients with clinical stage I to IVB esophageal squamous cell carcinoma were enrolled. Nedaplatin (10 mg/body/day) was administered daily and 5-FU (500 mg/body/day) was administered continuously for 20 days. Fractionated radiotherapy for a total dose of 50.4-66 Gy was administered together with chemotherapy. Additional chemotherapy with nedaplatin and 5-FU was optionally performed for a maximum of 5 courses after chemoradiotherapy. The primary end-point of this study was to evaluate the tumor response, and the secondary end-points were to evaluate the toxicity and the overall survival.</p> <p>Results</p> <p>Twenty-two patients (72.7%) completed the regimen of chemoradiotherapy. Twenty patients (60.6%) achieved a complete response, 10 patients (30.3%) a partial response. One patient (3.0%) had a stable disease, and 2 (6.1%) a progressive disease. The overall response rate was 90.9% (95% confidence interval: 75.7%-98.1%). For grade 3-4 toxicity, leukopenia was observed in 75.8% of the cases, thrombocytopenia in 24.2%, anemia in 9.1%, and esophagitis in 36.4%, while late grade 3-4 cardiac toxicity occurred in 6.1%. Additional chemotherapy was performed for 26 patients (78.8%) and the median number of courses was 3 (range, 1-5). The 1-, 2- and 3-year survival rates were 83.9%, 76.0% and 58.8%, respectively. The 1- and 2-year survival rates were 94.7% and 88.4% in patients with T1-3 M0 disease, and 66.2% and 55.2% in patients with T4/M1 disease.</p> <p>Conclusion</p> <p>The treatment used in our study may yield a high complete response rate and better survival for each stage of esophageal squamous cell carcinoma.</p> <p>Trial registration</p> <p>ClinicalTrials.gov Identifier: NCT00197444</p
T1069 Effect of Low-Dose Administration of Lansoprazole On the Gastric Mucosal Lesions Induced By Low-Dose Aspirin in Relation to Intragastric pH in Healthy Volunteers with Different CYP2C19 Genotypes
M1080 Correlation Between Genetic Mutations in 23s rRNA and gyrA of H. pylori Strains in Japan
S1085 Use of the 13C-Pantoprazole Breath Test to Predict CYP2C19 Phenotype and Efficacy of Proton Pump Inhibitors
Su1294 – Eradication Ratio and Adverse Events Incidence in the Aged Patients’ Helicobacter Pylori Eradication
W1741 Effect of Trastuzumab on Phosphorylated Histone H2AX Induced by Topoisomerase-1 Inhibitor (SN-38) in Gastric Cancer Cell Lines With or Without HER2 Expression
M1983 Influences of Renin-Angiotensin System-Related Gene Polymorphisms On Gastric Cancer Risks in Japan
T1079 Acid Inhibition in Early Phase By Intravenous Infusion of Omeprazole and/or Famotidine in Relation to Cytochrome P450 2C19 Genotype Status
M1068 The Degree and Duration of Acid Suppression During Treatment Is Related to Helicobacter pylori Eradication By Triple Therapy
M1125 Comparison of Triple Rabeprazole/Metronidazole/Sitafloxacin Therapy With Triple Rabeprazole/Amoxicillin/Sitafloxacin Therapy as the Third Rescue Regimen for Eradication of H. pylori
- …